close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.
The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo)
Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
CLICK HERE TO GET THE FOX NEWS APP
Petco revealed a data breach that exposed sensitive customer information. The company disclosed the details…
Baseball teams have long searched for a way to study the entire swing without sensors…
News of more than 120,000 Korean home cameras being hacked recently can shake your confidence…
Managing diabetes already brings stress from medications and long-term health risks. Regular glucose checks only…
Cybercriminals keep getting better at blending into the software you use every day. Over the…
A futuristic food dome at Expo 2025 Osaka-Kansai offered a surprising look at how cities…